Abstract Title:

Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.

Abstract Source:

Anticancer Res. 2015 Apr ;35(4):2199-204. PMID: 25862878

Abstract Author(s):

Yoshihiro Yamamoto, Kazushi Watanabe, Ikuto Tsukiyama, Hiroshi Matsushita, Hiromitsu Yabushita, Katsuhiko Matsuura, Akihiko Wakatsuki

Article Affiliation:

Yoshihiro Yamamoto

Abstract:

AIM: The present study aimed to assess the efficacy of 15 mEq magnesium supplied as part of a prehydration regimen in preventing cisplatin-induced nephrotoxicity in patients undergoing therapy with cisplatin-alone (40 mg/m(2)/week) for cervical cancer.

PATIENTS AND METHODS: We studied 28 patients with cervical cancer. This prospective cohort study compared nephrotoxicity in patients who received hydration with and without magnesium sulfate (Mg-hydration group, n=14; non-Mg-hydration group, n=14).

RESULTS: Baseline characteristics, stage of cervical cancer, cisplatin dose and renal function did not differ significantly between the two groups. The serum creatinine level significantly increased from 0.58 to 0.75 mg/dl, and the estimated glomerular filtration rate significantly decreased from 85.1 to 66.5 ml/min by chemotherapy in the non-Mg-hydration group. In contrast, these levels did not change significantly in the Mg-hydration group.

CONCLUSION: A magnesium dose of 15 mEq was found to provide nephroprotective effects among patients with cervical cancer undergoing chemotherapy with cisplatin alone.

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.